Noting that bleeding is a well-known complication of all anticoagulant medicines", the EMA says Pradaxa (dabigatran) has been kept under close review by the agency???s Committee for Medicinal Products for Human Use (CHMP) since its initial authorisation in Europe back in March 2008 for the prevention of venous thromboembolic events following hip or knee replacement surgery.